Be smarter and faster with PRO Alerts on VNRX
There is research on this stock available only to PRO subscribers.
- VNRX blood based colorectal cancer test shows impressive results.
- VNRX cancer diagnostic platform could be the first accurate, cheap, and easy to use diagnostic of its kind addressing worldwide screening populations.
- Expecting multiple clinical milestones over the next 12 months.
- VNRX is trading at a fraction, 2%, of Exact Sciences valuation.
There are no Transcripts on VNRX.
We currently have no Breaking News on this stock.
VNRX vs. ETF Alternatives
VolitionRX is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats.<br />VolitionRX is managed by a well-respected team with extensive experience in diagnostics and... More
Other News & PR